This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast To

NEW YORK, April 10, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to

http://www.reportlinker.com/p01158259/European-Nuclear-Medicine-/-Radiopharmaceuticals-Market-[SPECT/PET-Radioisotopes-Technetium-F-18]-[Beta/Alpha-Radiation-Therapy-I131-Y-90]-[Applications-Cancer/Oncology-Cardiac]--Stable-Isotopes-Deuterium-C-13---Global-Trends--Forecast-to.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017]The European radioisotopes market was valued at $1.1 billion in 2012 and is poised to reach $1.6 billion in 2017 at a CAGR of 6.8%.A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, and other developed regions between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 and OSIRIS in France in 2018 is, however, a major threat for manufacturers.The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy. Germany is the largest consumer market for radiopharmaceuticals in the Europe. There are only 5 major reactors in the world and most of the countries are completely dependent on the productions from those reactors. A few countries such as Poland, Australia, Argentina, and South Africa have started producing Tc-99m at their own reactors in a small scale. Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Covidien, Plc ( Ireland), GE Healthcare (U.K.), IBA Group ( Belgium), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. ( Canada), and Siemens Healthcare (PETNET) ( Germany).The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.) and Isotec (Sigma Aldrich) (U.S.) - in 2012; they jointly contributed more than 50% to the European revenue.

Scope of the ReportThe radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by geography ( North America, Europe, Asia, and Rest of the World) to provide in-depth information on the European scenario. European Radiopharmaceuticals MarketDiagnosticSPECTTc-99mTl-201Ga-67I-123OthersPETF-18Rb-82OthersTherapyBeta emittersI-131Sm-153Re-186 Y-90Lu-177OthersAlpha emittersBrachytherapyCs-131I-125Pd-103Ir-192Others European Enriched Stable Isotopes MarketDeuteriumOxygen-18Carbon-13Nitrogen-15Others Radiopharmaceutical and Stable Isotope Markets, By Geography France Germany Italy SpainU.K. RussiaRoE

TABLE OF CONTENTS 1 INTRODUCTION 25 1.1 KEY TAKE-AWAYS 25 1.2 REPORT DESCRIPTION 25 1.3 MARKETS COVERED 27 1.4 STAKEHOLDERS 28 1.5 RESEARCH METHODOLOGY 29 1.5.1 MARKET SIZE 29 1.5.2 MARKET SHARE 30 1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 30 1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 30 1.5.5 ASSUMPTIONS 31 2 EXECUTIVE SUMMARY 32 3 MARKET OVERVIEW 37 3.1 INTRODUCTION 38 3.2 DEFINITION OF RADIOPHARMACEUTICALS 38 3.3 EVOLUTION 39 3.4 MARKET SEGMENTATION 40 3.4.1 RADIOPHARMACEUTICALS 40 3.4.2 STABLE ISOTOPES 41 3.5 MARKET DYNAMICS 42 3.5.1 DRIVERS 43 3.5.1.1 Increasing incidence of cancer and cardiac ailments boosts the demand for radiopharmaceuticals 43 3.5.1.2 Increasing use of SPECT and PET scans results in rise of radiopharmaceutical usage 43 3.5.1.3 Rising awareness of radiopharmaceuticals to spur growth 44 3.5.1.4 Ready availability of radiopharmaceuticals from cyclotrons to goad the growth 44 3.5.2 RESTRAINTS 44 3.5.2.1 Shorter half-life of radiopharmaceuticals restricts the usage 44 3.5.2.2 High capital to limit the buying of scanners 45 3.5.2.3 Stringent regulatory guidelines and GMP to negatively impact growth 45 3.5.2.4 Competition from conventional diagnostic procedures 46 3.5.3 OPPORTUNITIES 46 3.5.3.1 Potential radioisotopes in the pipeline 46 3.5.3.2 Alpha radioimmunotherapy-based targeted cancer treatment 47 3.5.3.3 Alternative diagnostic radiopharmaceutical solutions 47 3.5.3.4 Cyclotron based production 48 3.5.3.5 Neurological applications 48 3.5.4 THREAT 48 3.5.4.1 Shutdown of nuclear reactors to impact production of radioisotopes 48 3.6 WINNING IMPERATIVES 49 3.6.1 INVESTMENTS ON NEW RADIOISOTOPES AND NOVEL APPLICATIONS 49 3.6.2 SHIFT TOWARDS LEU-BASED MO-99 PRODUCTION 49 3.7 BURNING ISSUES 50 3.7.1 HIGH COST OF PET CAMERAS 50 3.7.2 SHORTAGE IN SUPPLY OF TECHNETIUM-99M 50 3.8 REGULATORY AFFAIRS 51 3.8.1 GERMANY 51 3.8.1.1 German Medicinal Products Act (AMG) 51 3.8.1.2 Amendments to the German Medicinal Products Act (AMG) 52 3.8.2 FRANCE 52 3.8.2.1 Agence Française de la Securité Sanitaire des Produits de la Santé (AFSSAPS) 52 3.8.3 U.K. 53 3.8.3.1 The Medicines and Healthcare Products Regulatory Agency (MHRA) 53 3.8.4 SPAIN 53 3.8.5 ITALY 54 3.8.5.1 The Italian Pharmaceutical Agency (AIFA) 54 3.8.6 RUSSIA 54 3.8.6.1 The Federal Law 54 3.9 MARKET SHARE ANALYSIS 55 3.9.1 RADIOPHARMACEUTICALS MARKET 55 3.9.2 ENRICHED STABLE ISOTOPE MARKET 57 4 EUROPEAN RADIOPHARMACEUTICALS MARKET, BY ISOTOPE 58 4.1 INTRODUCTION 59 4.2 DIAGNOSTIC MARKET 59 4.2.1 OPPORTUNITY MATRIX 60 4.2.2 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) RADIOPHARMACEUTICALS 62 4.2.2.1 Technetium-99m (Tc-99m) 64 4.2.2.1.1 Tc-99m to decide growth trend of SPECT radioisotopes 66 4.2.2.1.2 Factors affecting Technetium-99m market 68 4.2.2.1.2.1 Technetium can combine with 31 different carrier molecules 68 4.2.2.1.2.2 Lack of availability of technetium 68 4.2.2.2 Thallium-201 (Tl-201) 68 4.2.2.2.1 Tl-201 is a potential substitute for Tc-99m 69 4.2.2.3 Gallium-67 (Ga-67) 70 4.2.2.3.1 Fluorine-18 (PET) might seize Ga-67 (SPECT) market share in the near future 70 4.2.2.4 Iodine (I-123) 71 4.2.2.5 Others 73 4.2.3 POSITRON-EMISSION TOMOGRAPHY (PET) RADIOPHARMACEUTICALS 75 4.2.3.1 Fluorine-18 77 4.2.3.1.1 FDG 77 4.2.3.1.2 Florbetapir 78 4.2.3.1.3 Factors affecting Fluorine-18 market 79 4.2.3.1.3.1 Rise in PET procedures increases demand for FDG 79 4.2.3.1.3.2 High generation costs of FDG 80 4.2.3.1.3.3 Need for speedy & efficient transportation 80 4.2.3.2 Rubidium-82 (Rb-82) 80 4.2.3.3 Others 81 4.3 THERAPEUTIC ISOTOPES 83 4.3.1 OPPORTUNITY MATRIX 84 4.3.2 BETA EMITTERS 85 4.3.2.1 Iodine-131 (I-131) 87 4.3.2.2 Yttrium-90 ( Y-90) 89 4.3.2.2.1 Y-90 market influenced by popularity of Nordion's TheraSphere 89 4.3.2.3 Samarium-153 (Sm-153) 90 4.3.2.4 Rhenium-186 (Re-186) 92 4.3.2.5 Lutetium-177 (Lu-177) 93 4.3.2.5.1 Lu-177 is a potential treatment option for neuroendocrine cancer 94 4.3.2.6 Others 95 4.3.2.6.1 Re-188 and P-33 are notable promising isotope 95 4.3.3 ALPHA EMITTERS 96 4.3.3.1 Radium-223 (Ra-223) & Alpharadin 97 4.3.3.1.1 Successful completion of Phase III trials in men with bone metastases from CRPC 99 4.3.3.1.2 First in-class alpha pharmaceutical 99 4.3.3.1.3 Alpharadin is advantageous over Taxotere, beta-therapy and brachytherapy 99 4.3.3.1.4 Success of Alpharadin 100 4.3.3.1.5 Porter's five forces analysis 100 4.3.3.1.6 SWOT analysis 102 4.3.3.2 Actinium-225 (Ac-225) 103 4.3.3.3 Lead-212 (Pb-212)/Bismuth-212 (Bi-212) 103 4.3.3.4 Astatine-211 (At-211) 103 4.3.3.5 Radium-224 (Ra-224) 103 4.3.3.6 Thorium-227 (Th-227) 104 4.3.4 BRACHYTHERAPY 104 4.3.4.1 Cesium-131 108 4.3.4.2 Iodine-125 109 4.3.4.3 Palladium-103 110 4.3.4.4 Iridium-192 111 4.3.4.5 Others 112 5 EUROPEAN RADIOPHARMACEUTICALS MARKET, BY APPLICATION/INDICATION 114 5.1 INTRODUCTION 115 5.2 DIAGNOSTIC APPLICATION 115 5.2.1 SPECT 116 5.2.1.1 Cardiology 118 5.2.1.2 Lymphoma 119 5.2.1.3 Thyroid 120 5.2.1.4 Neurology 122 5.2.1.4.1 Alzheimer's, dementia, and Parkinson's disease driving growth of the neurology SPECT market 122 5.2.1.5 Others 123 5.2.2 PET 124 5.2.2.1 Oncology 125 5.2.2.1.1 FDG F-18 has become a gold standard for oncology diagnosis using PET scan 126 5.2.2.2 Cardiology 127 5.2.2.3 Neurology 128 5.2.2.4 Others 129 5.3 THERAPEUTIC APPLICATION 131 5.3.1 THYROID 132 5.3.2 BONE METASTASIS 134 5.3.3 LYMPHOMA 135 5.3.4 ENDOCRINE TUMORS 136 5.3.5 OTHERS 138 6 EUROPEAN ENRICHED STABLE ISOTOPES MARKET 139 6.1 INTRODUCTION 140 6.2 MARKET OVERVIEW 141 6.3 MARKET DYNAMICS 142 6.3.1 DRIVERS 142 6.3.1.1 Stable isotopes are natural in origin & hence safe 142 6.3.1.2 Proteomics & system biology, major factors to boost the growth of stables 142 6.3.1.3 Medical applications propel stable isotopes market growth 142 6.3.2 RESTRAINTS 143 6.3.2.1 Harmful effects of high doses of stable isotopes affect market growth 143 6.3.2.2 High cost of stables isotope 143 6.4 ENRICHED STABLES MARKET, BY ISOTOPE 144 6.4.1 DEUTERIUM & O-18 ARE PROMISING ISOTOPES 145 6.4.2 CARBON-13 147 6.4.3 DEUTERIUM 148 6.4.4 OXYGEN-18 149 6.4.5 NITROGEN-15 150 6.4.6 OTHER STABLE ISOTOPES 151 6.5 ENRICHED STABLES MARKET, BY APPLICATION 152 6.5.1 DIAGNOSTIC & THERAPY 152 6.5.2 RESEARCH 154 6.5.3 PHARMACEUTICAL 155 6.5.4 INDUSTRIAL SECTOR 156 7 GEOGRAPHIC ANALYSIS 158 7.1 INTRODUCTION 158 7.2 GERMANY 159 7.3 FRANCE 165 7.4 U.K. 170 7.5 SPAIN 175 7.6 ITALY 180 7.7 RUSSIA 185 7.8 REST OF EUROPE 190 8 COMPETITIVE LANDSCAPE 196 8.1 INTRODUCTION 196 8.2 MERGERS & ACQUISITIONS 197 8.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES 198 8.4 NEW PRODUCTS LAUNCH 201 8.5 EXPANSIONS 203 8.6 OTHER DEVELOPMENTS 204 9 COMPANY PROFILES 208 9.1 COMPANIES 208 9.1.1 BRACCO IMAGING S.P.A. 208 9.1.2 CAMBRIDGE ISOTOPE LABORATORIES, INC. 211 9.1.3 CARDINAL HEALTH, INC. 215 9.1.4 COVIDIEN, PLC 221 9.1.5 ECZACIBASI-MONROL 226 9.1.6 FUJIFILM HOLDINGS CORPORATION 228 9.1.7 GE HEALTHCARE (SUBSIDIARY OF GENERAL ELECTRIC COMPANY) 233 9.1.8 IBA GROUP 239 9.1.9 ISOTEC, INC. (SIGMA-ALDRICH) 246 9.1.10 LANTHEUS MEDICAL IMAGING, INC. 250 9.1.11 NORDION, INC. 257 9.1.12 NTP RADIOISOTOPES (PTY), LTD. 264 9.1.13 PETNET SOLUTIONS, INC. (A SUBSIDIARY OF SIEMENS MEDICAL SOLUTIONS USA, INC.) 267 9.1.14 TAIYO NIPPON SANSO CORPORATION 272 9.1.15 ROTEM INDUSTRIES, LTD., INC. 276 9.1.16 URENCO LIMITED 278 9.2 INSTITUTES 282 9.2.1 AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION (ANSTO) 282 9.2.2 INSTITUTE OF ATOMIC ENERGY POLATOM RADIOISOTOPE CENTRE 285 9.2.3 INSTITUTE OF ISOTOPES CO., LTD. 287 9.2.4 INSTITUTE OF RADIOELEMENT (IRE) 290 LIST OF TABLES TABLE 1 EUROPE: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION) 33 TABLE 2 EUROPE: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION) 60 TABLE 3 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 63 TABLE 4 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 64 TABLE 5 INDICATIONS DIAGNOSED BY TC-99M 65 TABLE 6 EUROPE: TC-99M MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 67 TABLE 7 EUROPE: TL-201 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 69 TABLE 8 EUROPE: GA-67 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 71 TABLE 9 EUROPE: I-123 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 72 TABLE 10 EUROPE: OTHER RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 74 TABLE 11 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 76 TABLE 12 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 77 TABLE 13 EUROPE: F-18 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 79 TABLE 14 EUROPE: RB-82 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 81 TABLE 15 EUROPE: OTHER PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 82 TABLE 16 EUROPE: RADIOPHARMACEUTICAL MARKET, BY THERAPY, 2010 – 2017 ($MILLION) 83 TABLE 17 EUROPE: BETA EMITTER RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 86 TABLE 18 EUROPE: BETA EMITTER RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 87 TABLE 19 EUROPE: I-131 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 88 TABLE 20 EUROPE: Y-90 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 90 TABLE 21 EUROPE: SM-153 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 91 TABLE 22 EUROPE: RE-186 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 93 TABLE 23 EUROPE: LU-177 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 94 TABLE 24 EUROPE: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 96 TABLE 25 ALPHA EMITTERS VS BETA EMITTERS 97 TABLE 26 RADIOPHARMACEUTICALS CHARACTERISTICS & DOSE DELIVERY OVER TIME 105 TABLE 27 EUROPE: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 107 TABLE 28 EUROPE: BRACHYTHERAPY MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 108 TABLE 29 EUROPE: CS-131 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 109 TABLE 30 EUROPE: I-125 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 110 TABLE 31 EUROPE: PD-103 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 111 TABLE 32 EUROPE: IR-192 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 112 TABLE 33 EUROPE: OTHER BRACHYTHERAPY MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 113 TABLE 34 EUROPE: SPECT APPLICATION MARKET, 2010 – 2017 ($MILLION) 117 TABLE 35 EUROPE: CARDIOLOGY SPECT MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 118 TABLE 36 EUROPE: LYMPHOMA SPECT MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 120 TABLE 37 EUROPE: THYROID SPECT MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 121 TABLE 38 EUROPE: NEUROLOGY SPECT MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 123 TABLE 39 EUROPE: OTHER SPECT APPLICATIONS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 124 TABLE 40 EUROPE: PET APPLICATION MARKET, 2010 – 2017 ($MILLION) 125 TABLE 41 EUROPE: ONCOLOGY PET MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 126 TABLE 42 EUROPE: CARDIOLOGY PET MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 127 TABLE 43 EUROPE: NEUROLOGY PET MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 129 TABLE 44 EUROPE: OTHER PET APPLICATIONS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 130 TABLE 45 EUROPE: RADIOPHARMACEUTICAL THERAPEUTIC APPLICATION MARKET, 2010 – 2017 ($MILLION) 131 TABLE 46 EUROPE: RADIOPHARMACEUTICAL THERAPEUTIC APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 132 TABLE 47 EUROPE: RADIOPHARMACEUTICAL THYROID APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 133 TABLE 48 EUROPE: RADIOPHARMACEUTICAL BONE METASTASIS APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 135 TABLE 49 EUROPE: RADIOPHARMACEUTICAL LYMPHOMA APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 136 TABLE 50 EUROPE: RADIOPHARMACEUTICAL ENDOCRINE APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 137 TABLE 51 EUROPE: RADIOPHARMACEUTICAL OTHER APPLICATIONS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 138 TABLE 52 EUROPE: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 144 TABLE 53 EUROPE: STABLE ISOTOPE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 146 TABLE 54 EUROPE: CARBON STABLE ISOTOPE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 147 TABLE 55 EUROPE: DEUTERIUM STABLE ISOTOPE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 148 TABLE 56 EUROPE: OXYGEN STABLE ISOTOPE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 149 TABLE 57 EUROPE: NITROGEN STABLE ISOTOPE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 150 TABLE 58 EUROPE: OTHER STABLE ISOTOPE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 151 TABLE 59 EUROPE: ENRICHED STABLE ISOTOPE MARKET, BY APPLICATION, 2010 – 2017 ($MILLION) 152 TABLE 60 EUROPE: STABLE ISOTOPES MARKET FOR DIAGNOSTIC & THERAPEUTIC APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 153 TABLE 61 EUROPE: STABLE ISOTOPES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 155 TABLE 62 EUROPE: STABLE ISOTOPES MARKET FOR PHARMACEUTICAL APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 156 TABLE 63 EUROPE: STABLE ISOTOPES MARKET FOR INDUSTRIAL APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 157 TABLE 64 GERMANY: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 161 TABLE 65 GERMANY: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 162 TABLE 66 GERMANY: RADIOPHARMACEUTICAL MARKET, BY THERAPY,| 2010 – 2017 ($MILLION) 162 TABLE 67 GERMANY: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 163 TABLE 68 GERMANY: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 164 TABLE 69 GERMANY: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 165 TABLE 70 FRANCE: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 166 TABLE 71 FRANCE: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 167 TABLE 72 FRANCE: RADIOPHARMACEUTICAL MARKET, BY THERAPY, 2010 – 2017 ($MILLION) 167 TABLE 73 FRANCE: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 168 TABLE 74 FRANCE: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 169 TABLE 75 FRANCE: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 170 TABLE 76 U.K.: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 171 TABLE 77 U.K.: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 172 TABLE 78 U.K.: RADIOPHARMACEUTICAL MARKET, BY THERAPY, 2010 – 2017 ($MILLION) 172 TABLE 79 U.K.: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 173 TABLE 80 U.K.: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 174 TABLE 81 U.K.: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 175 TABLE 82 SPAIN: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 176 TABLE 83 SPAIN: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 177 TABLE 84 SPAIN: RADIOPHARMACEUTICAL MARKET, BY THERAPY, 2010 – 2017 ($MILLION) 177 TABLE 85 SPAIN: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 178 TABLE 86 SPAIN: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 179 TABLE 87 SPAIN: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 180 TABLE 88 ITALY: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 181 TABLE 89 ITALY: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 182 TABLE 90 ITALY: RADIOPHARMACEUTICAL MARKET, BY THERAPY, 2010 – 2017 ($MILLION) 182 TABLE 91 ITALY: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 183 TABLE 92 ITALY: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 184 TABLE 93 ITALY: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 185 TABLE 94 RUSSIA: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 186 TABLE 95 RUSSIA: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 187 TABLE 96 RUSSIA: RADIOPHARMACEUTICAL MARKET, BY THERAPY, 2010 – 2017 ($MILLION) 187 TABLE 97 RUSSIA: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 188 TABLE 98 RUSSIA: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 189 TABLE 99 RUSSIA: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 190 TABLE 100 ROE: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 191 TABLE 101 ROE: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 192 TABLE 102 ROE: RADIOPHARMACEUTICAL MARKET, BY THERAPY, 2010 – 2017 ($MILLION) 192 TABLE 103 ROE: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 193 TABLE 104 ROE: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 194 TABLE 105 ROE: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 195 TABLE 106 MERGERS & ACQUISITIONS, 2010 – 2012 197 TABLE 107 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2013 198 TABLE 108 NEW PRODUCTS LAUNCH, 2010 –2013 201 TABLE 109 EXPANSIONS, 2010 –2012 203 TABLE 110 OTHER DEVELOPMENTS, 2010 – 2012 204 TABLE 111 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION) 212 TABLE 112 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION) 213 TABLE 113 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION) 216 TABLE 114 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION) 217 TABLE 115 COVIDIEN, PLC: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($MILLION) 222 TABLE 116 COVIDIEN, PLC: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION) 222 TABLE 117 COVIDIEN, PLC: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION) 224 TABLE 118 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION) 230 TABLE 119 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION) 230 TABLE 120 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($BILLION) 234 TABLE 121 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($BILLION) 235 TABLE 122 IBA GROUP: MARKET REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 240 TABLE 123 IBA GROUP: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 241 TABLE 124 ISOTEC INC.: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 247 TABLE 125 ISOTEC INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 248 TABLE 126 LANTHEUS: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 252 TABLE 127 LANTHEUS: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 252 TABLE 128 NORDION, INC.: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION) 259 TABLE 129 NORDION, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2017 259 TABLE 130 SIEMENS AG: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION) 268 TABLE 131 SIEMENS AG: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION) 268 TABLE 132 SIEMENS AG: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION) 269 TABLE 133 TAIYO NIPPON SANSO, CORP.: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION) 274 LIST OF FIGURES FIGURE 1 EUROPE: RADIOPHARMACEUTICALS MARKET, BY SEGMENT, 2010 – 2017 33 FIGURE 2 EUROPE: RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2012 ($MILLION) 34 FIGURE 3 EUROPE: STABLE ISOTOPES MARKET, 2012 – 2017 ($MILLION) 36 FIGURE 4 EVOLUTION OF RADIOPHARMACEUTICALS 39 FIGURE 5 RADIOPHARMACEUTICALS MARKET SEGMENTATION 40 FIGURE 6 ENRICHED STABLE ISOTOPES MARKET SEGMENTATION 41 FIGURE 7 MARKET DYNAMICS 42 FIGURE 8 EUROPEAN RADIOPHARMACEUTICALS: MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2012 55 FIGURE 9 EUROPEAN ENRICHED STABLE ISOTOPE: MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2012 57 FIGURE 10 OPPORTUNITY MATRIX: EUROPEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET (2012) 61 FIGURE 11 SPECT RADIOPHARMACEUTICALS MARKET SHARE (2012) 62 FIGURE 12 PET RADIOPHARMACEUTICALS MARKET SHARE(2012) 75 FIGURE 13 OPPORTUNITY MATRIX: EUROPEAN THERAPEUTIC RADIOPHARMACEUTICALS MARKET (2012) 84 FIGURE 14 RA-223 DECAY CHAIN 98 FIGURE 15 PORTER'S FIVE FORCES ANALYSIS FOR ALPHARADIN 101 FIGURE 16 SWOT ANALYSIS OF ALPHARADIN 102 FIGURE 17 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET, BY INDICATION (2012) 116 FIGURE 18 KEY GROWTH STRATEGIES, 2010 –2013 196 FIGURE 19 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($BILLION) 212 FIGURE 20 CARDINAL HEALTH, INC.: TOTAL REVENUE, 2010 – 2012 ($BILLION) 216 FIGURE 21 COVIDIEN, PLC: RADIOPHARMACEUTICALS REVENUE, 2010 – 2012 ($BILLION) 223 FIGURE 22 FUJIFILM HOLDINGS CORP: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($BILLION) 229 FIGURE 23 GENERAL ELECTRIC COMPANY: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($BILLION) 234 FIGURE 24 IBA GROUP: TOTAL MARKET REVENUE, 2009 – 2011 ($MILLION) 240 FIGURE 25 ISOTEC INC.: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($BILLION) 247 FIGURE 26 LANTHEUS: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION) 251 FIGURE 27 NORDION, INC.: TOTAL MARKET REVENUE, 2010 – 2012 ($BILLION) 258 FIGURE 28 TAIYO NIPPON SANSO, CORP.: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($BILLION) 273 FIGURE 29 URENCO LIMITED: TOTAL MARKET REVENUE, 2009 – 2011 ($BILLION) 279

To order this report: Medical_Imaging Industry: European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to

Contact Clare: clare@reportlinker.comUS:(339) 368 6001Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs